Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for Treatment Resistant Depression
NCT01407575Phase 3Completed
- Sponsor
- University of Pittsburgh
- Start
- Sep 2011
- Primary completion
- Aug 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Buprenorphine with Placebo (2 arms). Primary endpoints: Montgomery Asberg Depression Rating Scale at 6 weeks, Blood Pressure at 6 weeks and 3 more. Started Sep 2011; status: completed.
02
Drugs
buprenorphine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01407575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01407575.